Published on: Jul 05, 2017 at Journal of Clinical Oncology

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

By : Journal of Clinical Oncology

New research looks into whether higher-dose trastuzumab plus chemotherapy increases overall survival for gastric cancer patients. 

Read More